Algorithm theoretical basis document for the precipitation product processors of the NWC/GEO

NWC/CDOP3/GEO/AEMET/SCI/ATBD/Precipitation, Issue1 , Rev. 0.1

Productos meteorológicos del NWC SAF

Ponencia presentada en: VI Simposio Nacional de Predicción, celebrado en los servicios centrales de AEMET, en Madrid, del 17 al 19 de septiembre de 2018.Los datos que se extraen de los satélites son mucho más que meras imágenes individuales. Trabajando sobre ellas y combinando unas con otras podemos extraer una serie de productos muy útiles para el pronóstico inmediato o nowcasting. Con este fin, el NWC SAF (Satellite Application Facility on support to Nowcasting) genera y difunde los productos y servicios operativos de EUMETSAT, para lo que pone a disposición de los usuarios un software con el que poder generar las herramientas que a todo predictor le serán de suma utilidad cuando haya que tomar decisiones en un periodo de una a tres o seis horas

Nowcasting SAF (NWC SAF) led by AEMET

Ponencia presentada en: XIX Congreso de la Asociación Española de Teledetección celebrado en Pamplona del 29 de junio al 1 de julio de 2022.[ES]El objetivo de la red de SAFs de EUMETSAT es obtener productos derivados de satélites para poder optimizar el uso de los datos de los satélites meteorológicos. Cada SAF (Satellite Application Facility) es un consocio de varios servicios meteorológicos y otras instituciones de los estados miembros de EUMETSAT y está especializado en un área concreta: composición atmosférica, clima, análisis de la superficie de la tierra, del océano, hidrología, predicción inmediata, para modelos numéricos y radio ocultación. En particular el SAF de Nowcasting (NWC SAF) es un consorcio liderado por AEMET en el que participan además los servicios meteorológicos de Francia, Austria, Suecia y Rumanía. Su objetivo es la generación de productos para su aplicación en Nowcasting o predicción inmediata y predicción a muy corto plazo. El SAF de Nowcasting desarrolla, implementa y distribuye paquetes de software con los que se pueden generar productos a partir de datos de satélites polares y geoestacionarios. Estos productos incluyen productos de nubes, de inestabilidad atmosférica, de precipitación, de iniciación de convección y de identificación y seguimiento de células convectivas, de vientos, de extrapolación de imágenes e identificación de ciertos fenómenos meteorológicos como el doblamiento de la tropopausa y ondas de gravedad. Estos productos son de utilidad para el seguimiento de fenómenos meteorológicos en tiempo real, con especial interés en el seguimiento de los fenómenos adversos, con aplicaciones también en el ámbito de la meteorología aeronáutica o en asimilación en modelos numéricos. La última versión del software para satélites geoestacionarios y los planes de futuro del NWC SAF son presentados.[EN]The objective of the EUMETSAT SAF Network is the generation of satellite derived products to contribute to the optimum use of the meteorological satellite data. Each SAF (Satellite Application Facility) is a Consortium of meteorological services and other institutions of the EUMETSAT member states, and is specialised in a concrete area: atmospheric composition, climate, land surface analysis, ocean, hydrology, nowcasting, numerical weather prediction and radio occultation. The Nowcasting SAF (NWC SAF) is a Consortium of the meteorological services of Spain, France, Austria, Sweden and Romania and is led by AEMET. Its objective is to ensure the optimum use of the satellite data on its application to nowcasting. For this, the NWC SAF develops, maintains and distributes software packages for geostationary and polar satellites that allow the generation of satellite products for nowcasting applications. These include cloud products, stability products, precipitation products, convection initiation, detection, characterization and tracking of convective cells, image and product extrapolation in time and identification of meteorological phenomena like tropopause folding and gravity waves. These products are of great interest for nowcasting, in particular for the tracking of severe weather, and also have applications in aviation meteorology and assimilation in NWP models. The more recent software version for geostationary satellites and the future plans of the NWC SAF are presented

Use of NWCSAF NWC/GEO Software Package with MSG, HIMAWARI-8/9 and GOES-13/16 Satellites

Ponencias presentadas en: Joint EUMETSAT/AMS/NOAA Conference 2019 celebrada en Boston del 30 de septiembre al 4 de octubre de 2019

The nowcasting SAF products and services: recent improvements in the new SW packages PPS v2018 and GEO v2018 and future plans

Presentación realizada en la 3rd European Nowcasting Conference, celebrada en la sede central de AEMET en Madrid del 24 al 26 de abril de 2019

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

Knowledge about clonal diversity and selection is critical to understand multiple myeloma (MM) pathogenesis, chemoresistance and progression. If targeted therapy becomes reality, identification and monitoring of intraclonal plasma cell (PC) heterogeneity would become increasingly demanded. Here we investigated the kinetics of intraclonal heterogeneity among 116 MM patients using 23-marker multidimensional flow cytometry (MFC) and principal component analysis, at diagnosis and during minimal residual disease (MRD) monitoring. Distinct phenotypic subclones were observed in 35116 (30%) newly diagnosed MM patients. In 1035 patients, persistent MRD was detected after 9 induction cycles, and longitudinal comparison of patient-paired diagnostic vs MRD samples unraveled phenotypic clonal tiding after therapy in half (510) of the patients. After demonstrating selection of distinct phenotypic subsets by therapeutic pressure, we investigated whether distinct fluorescence-activated cell-sorted PC subclones had different clonogenic and cytogenetic profiles. In half (510) of the patients analyzed, distinct phenotypic subclones showed different clonogenic potential when co-cultured with stromal cells, and in 611 cases distinct phenotypic subclones displayed unique cytogenetic profiles by interphase fluorescence in situ hybridization, including selective del(17p13). Collectively, we unravel potential therapeutic selection of preexisting diagnostic phenotypic subclones during MRD monitoring; because phenotypically distinct PCs may show different clonogenic and cytogenetic profiles, identification and follow-up of unique phenotypic-genetic myeloma PC subclones may become relevant for tailored therapy.Peer Reviewe

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

Spanish Myeloma Group (GEM) and Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups: et al.Multiple myeloma remains largely incurable. However, a few patients experience more than 10 years of relapsefree survival and can be considered as operationally cured. Interestingly, long-term disease control in multiple myeloma is not restricted to patients with a complete response, since some patients revert to having a profile of monoclonal gammopathy of undetermined significance. We compared the distribution of multiple compartments of lymphocytes and dendritic cells in the bone marrow and peripheral blood of multiple myeloma patients with long-term disease control (n=28), patients with newly diagnosed monoclonal gammopathy of undetermined significance (n=23), patients with symptomatic multiple myeloma (n=23), and age-matched healthy adults (n=10). Similarly to the patients with monoclonal gammopathy of undetermined significance and symptomatic multiple myeloma, patients with long-term disease control showed an expansion of cytotoxic CD8 + T cells and natural killer cells. However, the numbers of bone marrow T-regulatory cells were lower in patients with long-term disease control than in those with symptomatic multiple myeloma. It is noteworthy that B cells were depleted in patients with monoclonal gammopathy of undetermined significance and in those with symptomatic multiple myeloma, but recovered in both the bone marrow and peripheral blood of patients with long-term disease control, due to an increase in normal bone marrow B-cell precursors and plasma cells, as well as pre-germinal center peripheral blood B cells. The number of bone marrow dendritic cells and tissue macrophages differed significantly between patients with long-term disease control and those with symptomatic multiple myeloma, with a trend to cell count recovering in the former group of patients towards levels similar to those found in healthy adults. In summary, our results indicate that multiple myeloma patients with long-term disease control have a constellation of unique immune changes favoring both immune cytotoxicity and recovery of B-cell production and homing, suggesting improved immune surveillance.This work was supported by the Cooperative Research Thematic Network (RTICCs; RD06/0020/0006 and G03/136), Instituto de Salud Carlos III/ Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370) and Consejeria de Educacion (GR37) and Consejería de Sanidad, Junta de Castilla y León, Valladolid, Spain (557/A/10). The authors also thank the Fundación Carolina-BBVA for supporting and promoting the exchange of medical researchers from Latin America to Spain.Peer Reviewe

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in peripheral blood (PB) of virtually all MM cases and are prognostic, but their applicability for noninvasive screening has been poorly investigated. Here, we used next-generation flow (NGF) cytometry to isolate matched CTCs and BM tumor cells from 53 patients and compared their genetic profile. In eight cases, tumor cells from extramedullary (EM) plasmacytomas were also sorted and whole-exome sequencing was performed in the three spatially distributed tumor samples. CTCs were detectable by NGF in the PB of all patients with MM. Based on the cancer cell fraction of clonal and subclonal mutations, we found that ~22% of CTCs egressed from a BM (or EM) site distant from the matched BM aspirate. Concordance between BM tumor cells and CTCs was high for chromosome arm-level copy number alterations (≥95%) though not for translocations (39%). All high-risk genetic abnormalities except one t(4;14) were detected in CTCs whenever present in BM tumor cells. Noteworthy, ≥82% mutations present in BM and EM clones were detectable in CTCs. Altogether, these results support CTCs for noninvasive risk-stratification of MM patients based on their numbers and genetic profile.This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00236, CB16/12/00369, CB16/12/00489, and CB16/12/00400); by Cancer Research UK [C355/A26819] and FC AECC and AIRC under the Accelerator Award Program; by the Instituto de Salud Carlos III, FCAECC and co-financed by FEDER (ERANET-TRANSCAN-2 iMMunocell AC17/00101); the Spanish Ministry of Science and Innovation and co-financed by FSE (Torres Quevedo fellowship, PTQ-16-08623); the Black Swan Research Initiative of the International Myeloma Foundation; European Research Council (ERC) under the European Commission’s H2020 Framework Programme (MYELOMANEXT, 680200); the Qatar National Research Fund (QNRF) Award No. 7-916-3-237; the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV); the Leukemia Research Foundation; and the Multiple Myeloma Research Foundation (MMRF) under the 2019 Research Fellowship Award

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (N = 94), MGUS (N = 20) and multiple myeloma (MM, N = 52) vs. healthy adults (N = 30). MFC detected clonality in virtually all AL amyloidosis (99%) patients. Furthermore, we developed an automated risk-stratification system based on BMPCs features, with independent prognostic impact on progression-free and overall survival of AL amyloidosis patients (hazard ratio: ≥ 2.9;P ≤ .03). Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUC = 0.74;P < .001), and might potentially be used as biomarkers for the identification of MGUS and MM patients, who are candidates for monitoring pre-symptomatic organ damage related to AL amyloidosis. Altogether, this study addressed the need for consensus on how to use flow cytometry in AL amyloidosis, and proposes a standardized MFC-based automated risk classification ready for implementation in clinical practice

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM). Thus, characterization of the minor MRD subclone may represent a unique model to understand chemoresistance, but to our knowledge, the phenotypic and genetic features of the MRD subclone have never been investigated. Here, we compared the antigenic profile of MRD vs diagnostic clonal PCs in 40 elderly MM patients enrolled in the GEM2010MAS65 study and showed that the MRD subclone is enriched in cells overexpressing integrins (CD11a/CD11c/CD29/CD49d/CD49e), chemokine receptors (CXCR4), and adhesion molecules (CD44/CD54). Genetic profiling of MRD vs diagnostic PCs was performed in 12 patients; 3 of them showed identical copy number alterations (CNAs), in another 3 cases, MRD clonal PCs displayed all genetic alterations detected at diagnosis plus additional CNAs that emerged at the MRD stage, whereas in the remaining 6 patients, there were CNAs present at diagnosis that were undetectable in MRD clonal PCs, but also a selected number of genetic alterations that became apparent only at the MRD stage. The MRD subclone showed significant downregulation of genes related to protein processing in endoplasmic reticulum, as well as novel deregulated genes such as ALCAM that is prognostically relevant in MM and may identify chemoresistant PCs in vitro. Altogether, our results suggest that therapy-induced clonal selection could be already present at the MRD stage, where chemoresistant PCs show a singular phenotypic signature that may result from the persistence of clones with different genetic and gene expression profiles. This trial was registered at www.clinicaltrials.gov as #NCT01237249